How do you pay?

How to pay the least

Ask for the cash price

Lenvima

We didn’t find one.

What to do

  1. Ask your pharmacy for Lenvima’s cash price, and one or two other pharmacies too.
  2. Lenvima’s savings card works only with insurance from a job or one you bought.

Other ways

Free from the maker, if you qualify LENVIMA Patient Assistance Program. Patient must have a household income equal to or less than 500 percent of the Federal Poverty Level. Or call 1-866-613-4724.

See if you qualify 

Compare every option

Brand name

Lenvima, the original

Cash priceAsk the pharmacy
Ways to save on Lenvima

The maker’s card

LENVIMA Co-pay Program

Savings card from Eisai

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

The card takes up to $10,000 a year off your co-pay.

Sign up on eisaipatientsupport.com 

Or call 1-866-613-4724.

In the maker’s words

“With the LENVIMA Co-pay Program, eligible, commercially insured patients could pay as little as $0 out of pocket for their prescription.”

From the maker’s offer on eisaipatientsupport.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

We didn’t find one.

Not soldNone found

What it’s used for

What the FDA label says

LENVIMA is a kinase inhibitor that is indicated:

Differentiated Thyroid Cancer

  • For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).

Renal Cell Carcinoma

  • In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
  • In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
  • In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.

Hepatocellular Carcinoma

  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Endometrial Carcinoma

  • In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Source: the FDA label for Lenvima (Eisai Inc.), October 14, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.